Evolocumab Application in Real World From a Single-Center Registry in China

Am J Ther. 2023 May 1;30(3):e293-e296. doi: 10.1097/MJT.0000000000001373.

Authors

Affiliations

¹ Department of Endocrinology&Cardiometabolic Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
² Department of Structural Heart Diseases Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

PMID: 37278711
DOI: 10.1097/MJT.0000000000001373

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Anticholesteremic Agents* / therapeutic use
China / epidemiology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Proprotein Convertase 9
Registries
Treatment Outcome

Substances

evolocumab
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
Proprotein Convertase 9
Hydroxymethylglutaryl-CoA Reductase Inhibitors